LivaNova PLC(LIVN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 24.11 | EPS (ttm) | 3.37 | Insider Own | 0.41% | Shs Outstand | 55.0M | Perf Week | -0.02% |
| Market Cap | 4.48B | Forward P/E | 17.35 | EPS next Y | 7.51% | Insider Trans | -5.49% | Shs Float | 54.9M | Perf Month | 6.21% |
| Enterprise Value | 4.31B | PEG | 1.68 | EPS next Q | 1.06 | Inst Own | 110.83% | Short Float | 11.3% | Perf Quarter | 1.39% |
| Income | 0.19B | P/S | 3.04 | EPS this Y | 11.71% | Inst Trans | -0.18% | Short Ratio | 9.61 | Perf Half Y | 35.19% |
| Sales | 1.47B | P/B | 3.37 | EPS next 5Y | 10.32% | ROA | 7.33% | Short Interest | 6.20M | Perf YTD | 32.05% |
| Book/sh | 24.07 | P/C | 8.66 | EPS past 3/5Y | -40.2% 9.06% | ROE | 15.4% | 52W High | -5.26% ($85.76) | Perf Year | 52.32% |
| Cash/sh | 9.38 | P/FCF | 30.18 | Sales past 3/5Y | 10.75% 8.24% | ROIC | 11.32% | 52W Low | 66.43% ($48.82) | Perf 3Y | 72.18% |
| Dividend Est. | - | EV/EBITDA | 15.15 | EPS Y/Y TTM | 188.56% | Gross Margin | 68.24% | Volatility(W/M) | 1.93% 2.7% | Perf 5Y | 5.9% |
| Dividend TTM | - | EV/Sales | 2.93 | Sales Y/Y TTM | 12.39% | Oper. Margin | 15.01% | ATR (14) | 2.08 | Perf 10Y | 43.53% |
| Dividend Ex-Date | - | Quick Ratio | 1.21 | EPS Q/Q | 288.6% | Profit Margin | 12.81% | RSI (14) | 60.81 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.45 | Sales Q/Q | 10.8% | SMA20 | 4.04% ($78.09) | Beta | 0.92 | Target Price | $92.1 |
| Payout | - | Debt/Eq | 0.27 | Earnings | 2026/11/4 | SMA50 | 3.53% ($78.48) | Rel Volume | 0.75 | Prev Close | $80.66 |
| Employees | 3300 | LT Debt/Eq | 0.26 | EPS/Sales Surpr. | 15.12% 2.65% | SMA200 | 11.59% ($72.81) | Avg Volume(3M) | 0.65M | Price | $81.25 |
| IPO | 1993/2/11 | Option/Short | Yes/Yes | Trades | 7022 | Volume | 483,339 | Change | 0.73% |
🫀 This is a global medical device company that provides cardiopulmonary and neuromodulation medical devices. It supplies cardiopulmonary equipment, including heart surgery heart-lung machines and oxygenators, as well as neuromodulation devices for treating epilepsy and depression. It is a specialized medical device company spanning both cardiopulmonary and neuromodulation fields.
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
Next earnings report: November 4
5 days to go.
LIVN makes money exceptionally well
Of every $100 in sales, $15.01 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.7% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,515. Peers typically go for $1,750. Compared with its own 2-year average, it is 43% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +5.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 110.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #21 of 142 in the industry
Based on market cap of $4B.
FAQ
What kind of company is LIVN?
LIVN belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of LIVN?
The market cap of LIVN is approximately $4.5B, ranking 1,449 within its sector.
What is the P/E ratio of LIVN?
LIVN has a P/E ratio of approximately 24.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LIVN?
LIVN has recorded a 52-week high of $85.76 and a low of $48.82.
